CONMED Corporation Appoints Two New Board Members

CONMED Corporation has named Celine Martin and Jeff Mirviss to its Board of Directors. Martin serves on the Audit and Strategy committees, and Mirviss serves on the Compensation and Corporate Governance and Nominating committees.

With these appointments, CONMED is increasing the size of its board to include nine total directors.

“My fellow directors and I are delighted to welcome Celine Martin and Jeff Mirviss to the board, both highly accomplished leaders with extensive experience developed at two of the largest companies in the healthcare industry,” CONMED Board Chair LaVerne Council said. “Celine joins our board following a 30-year career at Johnson & Johnson, with deep global leadership experience in medtech and a track record of driving innovation and growth. Likewise, Jeff possesses nearly 30 years of experience at Boston Scientific, where he led complex, global medical device businesses with operational and commercial excellence. Their insight and expertise will be invaluable to the board as we advance CONMED’s long‑term strategy.”

Over three decades at Johnson & Johnson, both in the U.S. and internationally, Martin played a vital role in advancing the ambition of J&J MedTech, developing new categories and advancing the standard of care for atrial fibrillation, stroke, and minimally invasive surgery. Most recently, she served as company group chairman, leading the Cardiovascular & Specialty Solutions (CSS) Group from 2022 to 2025. As a member of the J&J MedTech leadership team, she ran a diverse portfolio of high-growth businesses including Electrophysiology, Neurovascular Intervention, Ear Nose and Throat, and Breast Aesthetics. Before that, Martin led the Ethicon Endo Surgery business, where she was instrumental in establishing the Robotic and Digital Surgery portfolio foundations.

Martin earned an MBA from Wake Forest University and a graduate degree in marketing from Normandy Business School. She also serves on the Board of Directors at H.B. Fuller.

Mirviss has more than 35 years of healthcare industry leadership experience. Most recently, he was executive vice president and global president of Peripheral Interventions at Boston Scientific from 2020 to 2025, where he led a multi-billion-dollar global business focused on therapies for vascular disease and cancer. In this role, he also had leadership responsibility for the company’s Latin America and Canada regions, as well as its government affairs function. Previously, Mirviss was senior vice president and global president of Peripheral Interventions from 2013 to 2020, and global president of Peripheral Interventions from 2011 to 2013. Before these roles, Mirviss held positions of increasing responsibility at Boston Scientific, including group vice president of Global Marketing for the company’s Cardiology, Rhythm and Vascular businesses.

Mirviss earned a B.I.S. in marketing from the University of Minnesota and an MBA from the University of St. Thomas.

“Celine and Jeff are outstanding additions to the board,” CONMED CEO Patrick Beyer stated. “Celine’s global strategic leadership and experience scaling high-growth medical technology businesses, combined with Jeff’s expertise in portfolio leadership and execution across large, global organizations, will strengthen our governance and support our continued focus on delivering long‑term value for patients, customers, and shareholders.”

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The company’s products are used by surgeons and other healthcare professionals in a various specialties, including orthopedics, general surgery, gynecology, and thoracic surgery.